Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
11,46 USD | +3,24% | +3,99% | +43,43% |
07/05 | Koersdoel AstraZeneca verhoogd; Antofagasta verlaagd | AN |
03/05 | AIB GROUP : Sterkere inkomstengroei en gunstige risicokosten |
Omzet 2024 * | 4,56 mld. 4,94 mld. | Omzet 2025 * | 4,34 mld. 4,71 mld. | Marktkapitalisatie | 12,44 mld. 13,5 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 1,76 mld. 1,91 mld. | Nettowinst (verlies) 2025 * | 1,56 mld. 1,69 mld. | EV/omzet 2024 * | 2,73 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,87 x |
K/w-verhouding 2024 * |
7,17
x | K/w-verhouding 2025 * |
7,46
x | Werknemers | 10.551 |
Dividendrendement 2024 * |
5,85% | Dividendrendement 2025 * |
6,2% | Vrij verhandelbaar | 67,6% |
Recentste transcriptie over AIB Group plc
1 dag | +3,24% | ||
1 week | +3,99% | ||
Lopende maand | +9,19% | ||
1 maand | +4,66% | ||
3 maanden | +40,44% | ||
6 maanden | +31,72% | ||
Lopend jaar | +43,43% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 01-01-16 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 01-09-13 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James Pettigrew
CHM | Chairman | 65 | 28-10-21 |
Basil Geoghegan
BRD | Director/Board Member | - | 04-09-19 |
Colin Hunt
CEO | Chief Executive Officer | 54 | 01-01-16 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
21-05-24 | 11,46 | +3,24% | 5 600 |
20-05-24 | 11,1 | -1,60% | 4 953 |
17-05-24 | 11,28 | +1,53% | 725 |
16-05-24 | 11,11 | +0,54% | 1 712 |
15-05-24 | 11,05 | +0,27% | 2 188 |
uitgestelde koers OTC Markets, 21 mei 2024 om 19:17 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,30% | 573 mld. | |
+17,76% | 310 mld. | |
+24,61% | 258 mld. | |
+24,87% | 214 mld. | |
+26,67% | 190 mld. | |
+32,89% | 174 mld. | |
+10,26% | 331 mld. | |
+7,86% | 150 mld. | |
+8,68% | 136 mld. |